Compared with standard AUD medications, the use of semaglutide and liraglutide was linked to a lower risk for alcohol use ...

The popular glucagon-like peptide-1 (GLP-1) receptor agonists known to help in weight loss as well as manage blood sugar can ...

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular ...

The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid ...

The glucose-lowering and weight-reducing drug class appears to benefit the heart and kidneys in people with lupus and lupus nephritis, independently of glucose-lowering and weight loss.

The combined reduction in the risk of kidney failure, worsening kidney function and death due to kidney disease was 19%, ...

Lexaria Bioscience (LEXX) announced that dosing has been completed for human pilot study #3 investigating a DehydraTECH-processed version of ...

In the US, liraglutide, semaglutide, and tirzepatide are currently under investigation for their ability to stimulate weight ...

The Healthcare sector in India grew strongly in Q2 of FY25, with revenue increasing by 17.6 per cent year on year (YoY), ...

This study estimates that approximately one-third of U.S. adults without diabetes who were eligible for weight loss treatment with ...

Diabetes and obesity drugs have been found to reduce the risk of kidney failure and protect cardiovascular health in people ...

In clinical trials, most participants taking semaglutide or tirzepatide (Mounjaro, Zepbound) to treat obesity lost an average ...